Gene delivery system for promoting aging of tumor cells as well as preparation method and application of gene delivery system
By inhibiting the expression of CTTN mRNA, using RNA interference technology to silence the expression of CTTN and activate p53, the aging of tumor cells and anti-tumor growth and metastasis are achieved, and the problems of DNA damage and tumor progression in the prior art are solved, and a kind of problem is provided. A new safe and efficient treatment method.
Patent Information
- Application Number
- CN202310654283.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-02
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is prone to DNA damage and promote tumor progression when inducing tumor cell aging, and lacks new treatment methods that do not cause DNA damage and have anti-tumor growth and metastasis effects.
A gene delivery system is adopted to inhibit the expression of CTTN mRNA and RNA interference technology is used to silence the expression of CTTN, thereby inducing tumor cell aging, activate p53, and achieving anti-tumor growth and metastasis. The system includes designed shRNA and gene delivery vectors, such as lentiviral vectors, for targeting CTTN mRNA.
Effectively reduce CTTN expression, induce tumor cell aging, significantly inhibit tumor growth and metastasis, avoid the side effects of DNA damage and tumor progression, and have high specificity and safety.
Smart Images

Figure CN119061008A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicine, and in particular to a gene delivery system for promoting tumor cell senescence, and a preparation method and application thereof. Background Art
[0002] Tumor cells have the potential for unlimited proliferation, and their growth regulation is disordered. One characteristic of cell senescence is that cells irreversibly enter a state of cell growth arrest, so inducing tumor cell senescence can exert an anti-tumor effect. At present, the main technical method for inducing tumor cell senescence is to use chemotherapy drugs. Chemotherapeutic drugs usually induce DNA damage and induce high expression of p53, thereby activating the expression of p21 (CDKN1A, Cyclin-dependent kinase inhibitor 1) to induce tumor cell senescence. In addition, overexpression or activation of the expression of oncogenes KRAS and Braf can promote the expression of p16 (CDKN2A, Cyclin-dependent kinase inhibitor 2A) and induce tumor cell senescence.
[0003] Tumor cell senescence induced by chemotherapy drugs can cause DNA damage and lead to serious side effects, which is a major disadvantage of this method. Although activation or overexpression of KRAS and BRAF genes can cause senescence in some tumor cells, since KRAS and BRAF are oncogenes, they may promote tumor progression. Therefore, there is an urgent need for a new type of drug for treating tumors that does not cause DNA damage and does not promote tumor progression. Summary of the invention
[0004] In view of the defects in the prior art, the present invention proposes a gene delivery system for promoting tumor cell senescence and its preparation method and application. The main purpose of the present invention is to induce tumor cell senescence by efficiently silencing the expression of CTTN and exert anti-tumor growth and metastasis effects.
[0005] The present invention provides a shRNA for inhibiting CTTN expression, wherein the shRNA comprises a sense chain of an RNAi molecule and an antisense chain of the RNAi molecule, wherein the antisense chain of the RNAi molecule hybridizes with a target sequence on a CTTN gene mRNA, and the nucleotide sequence of the shRNA is CCGG-the sense chain of the RNAi molecule-CTCGAG-the antisense chain of the RNAi molecule-TTTTTG.
[0006] Furthermore, the nucleotide sequence of the sense strand in the RNAi molecule contained in the shRNA is any one of SEQ ID NO.1 and SEQ ID NO.2.
[0007] The invention also provides a gene delivery system containing the shRNA sequence.
[0008] Furthermore, the gene delivery system includes but is not limited to viral vectors, liposomes, and nanoparticles.
[0009] Furthermore, the viral vector is a lentiviral vector pLKO-tet-on.
[0010] The present invention also provides the use of the shRNA or the gene delivery system in preparing drugs for treating tumors.
[0011] The present invention also provides the use of the shRNA or the gene delivery system in preparing a drug for inducing tumor cell senescence.
[0012] The present invention also provides the use of the shRNA or the gene delivery system in preparing a drug for activating p53.
[0013] The present invention also provides a method for preparing the gene delivery system, comprising the following steps: transferring the shRNA into the gene delivery system.
[0014] Furthermore, the gene delivery system includes but is not limited to viral vectors, liposomes, and nanoparticles.
[0015] In summary, compared with the prior art, the present invention achieves the following technical effects:
[0016] The gene delivery system of the present invention uses RNA interference technology to silence the expression of CTTN mRNA, and will not cause DNA damage. In addition, current studies have shown that CTTN has the ability to promote tumor cell movement and migration, and silencing the expression of CTTN mRNA does not promote the progression of tumor cells. Therefore, the method of inducing tumor cell senescence by silencing the expression of CTTN mRNA may be superior to the use of chemotherapy drugs and the use of high expression or activation of KRAS and BRAF to induce tumor cell senescence. The tumor cell senescence induced by silencing the expression of CTTN mRNA in the present invention depends on the activation of p53, and therefore has certain similarities with the cell senescence induced by chemotherapy drugs, but the tumor cell senescence induced by silencing CTTN mRNA may be more specific than chemotherapy drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0018] Figure 1 The present invention provides a lentiviral genome and a three-plasmid lentiviral assembly system based on the genome.
[0019] Figure 2 It is a key element of the pLKO-tet-on plasmid map.
[0020] Figure 3 The shRNA used in the present invention can effectively silence the expression of CTTN. pLKO-teton-CTTNshRNA1 and 2 were packaged into lentiviral particles, and after infecting melanoma cells Mel167 and A375, 300ng / ml doxycycline (Doxycycline, Dox) was added to treat the cells for 3 days, and then the total RNA and total protein of the cells were extracted to detect the expression of CTTN mRNA and CTTN protein in the cells. (A) Real-time quantitative PCR (RT-qPCR) was used to detect the expression of CTTN mRNA in Mel167 cells; (BD) Western blotting was used to detect the expression of CTTN protein in Mel167, A375 (melanoma cells) and BRx50 (breast cancer cells); shRNA1 refers to pLKO-tet-on-CTTN shRNA1; shRNA2 refers to pLKO-tet-on-CTTN shRNA2; CTL refers to pLKO.1-tet-on Control shRNA (negative control); Dox refers to doxycycline; ***, p<0.001.
[0021] Figure 4Knockdown of CTTN expression activates p53 and effectively induces tumor cell senescence. (AB) After doxycycline (Dox) induced shRNA1 expression to knockdown CTTN expression, Western blotting was used to detect the expression of CTTN protein in Mel167 and A375, as well as the markers of cell senescence p53, p21, p-RB and Lamin (CD) After doxycycline (Dox) induced shRNA1 expression to knock down CTTN expression, real-time quantitative PCR was used to detect the mRNA expression of Ki-67, a cell senescence marker; (E) After doxycycline (Dox) induced shRNA1 expression to knock down CTTN expression, the cell senescence β-galactosidase staining method was used to detect the β-galactosidase positive rate of A375 with CTTN knocked down, and the positive cells were senescent cells; (F) The cells with positive β-galactosidase staining in (E) were counted, and the positive cells were senescent cells; (G) After doxycycline (Dox) induced shRNA1 expression to knock down CTTN expression, Western blotting was used to detect the protein expression of p-ATM ser1981, p-ATR ser428, and p-H2A.x ser139 of Mel167, and Actin was used as the internal reference protein; (H) In p53 In the case of knockdown of p53 expression by shRNA, CTTN expression was silencing induced by doxycycline, and the protein expressions of cell senescence markers p21, p-RB, and Lamin B1 were detected by immunoblotting, and (I) the mRNA expression of Ki-67 was detected by real-time quantitative PCR; shRNA1 refers to pLKO-tet-on-CTTN shRNA1; CTL refers to pLKO.1-tet-onControl shRNA (negative control); Dox refers to doxycycline; p53 sh1 refers to pLKO.1-p53 shRNA; ***, p<0.001.
[0022] Figure 5Knockdown of CTTN expression effectively inhibits tumor proliferation and metastasis in vitro and in vivo. (AB) Cell proliferation assay of Mel-167 and A375 cells. Cells were seeded into 96-well plates and doxycycline was added to induce knockdown of CTTN. After 4 days of culture, cell proliferation was detected by CellTiter-Glo luminescent cell viability assay. Representative images show the state and density of cells on the last day; (C) Cell proliferation assay of breast cancer BRx50 cells. Cells were seeded into 6-well plates and doxycycline was added to induce knockdown of CTTN. After 14 days of culture (culture medium was changed every 4 days), cell proliferation was detected by CellTiter-Glo luminescent cell viability assay; (D) Growth curve of subcutaneous transplant tumors of Mel-167 in NCG mice; (EF) Tumor size and weight of subcutaneous transplant tumors of Mel-167 at the end of the experiment; (G) In vivo imaging of tail vein tumor metastasis model. The picture shows the results of in vivo imaging at the end point of the experiment (day 33); (H) Metastasis tumor growth curve drawn by statistical analysis of the in vivo imaging data at each time point in (F); shRNA1 refers to pLKO-tet-on-CTTN shRNA1; CTL refers to pLKO.1-tet-on Control shRNA (negative control); Dox refers to doxycycline; Dox at day1, Dox atday7, Dox at day19 refer to the administration of doxycycline-containing drinking water to mice on the 1st, 7th, and 19th days after the establishment of the animal model; **, p<0.01; ***, p<0.001.
[0023] Figure 6High expression of CTTN mRNA is associated with shorter overall survival of patients. Using the GEPIA online analysis platform (http: / / gepia.cancer-pku.cn / index.html), the TCGA dataset was used to analyze the overall survival of patients with skin melanoma (SKCM), hepatocellular carcinoma (LIHC), head and neck squamous cell carcinoma (NHSC), lung squamous cell carcinoma (LUSC), brain low-grade glioma (LLG), and pancreatic cancer (PAAD). The overall survival analysis of breast cancer patients was analyzed using the BCIP online platform (http: / / omicsnet.org / bcancer / database) to analyze the Metabric dataset. The blue line represents the CTTN mRNA low expression group, and the red line represents the CTTN mRNA high expression group; logrank p represents the significance of overall survival between the two groups, and logrank p<0.05 is significant; HR(high), hazard ratio HR(high)>1, indicating that in the same time period, patients with high expression of CTTN mRNA have a higher probability of death than patients with low expression of CTTN mRNA; n(high), n(low) are the number of patients. DETAILED DESCRIPTION
[0024] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only embodiments of a part of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work should fall within the scope of protection of the present invention.
[0025] The technical problem to be solved by the present invention is how to effectively induce senescence of tumor cells and produce highly effective anti-tumor growth and metastasis effects. CTTN (Cortactin, cortical actin) is highly expressed in tumors such as melanoma, colon cancer, and breast cancer, and is associated with poor prognosis, but there is currently no report showing that CTTN can regulate cell senescence. The present invention finds that CTTN can regulate tumor senescence. The present invention proves that CTTN is a key regulatory factor that regulates melanoma growth and senescence, and designs a shRNA method targeting CTTN mRNA. The present invention uses lentiviral particles to deliver short hairpin RNA (shRNA, small hairpin RNA) targeting CTTNmRNA to target cells. After the designed shRNA is delivered to the target cells through lentiviral particles, the expression of CTTN can be significantly reduced, and the anti-cancer gene p53 of tumor cells is activated to induce tumor cell senescence, while producing significant anti-tumor growth and metastasis effects. Silencing the expression of CTTN can induce cell senescence in melanoma cells, and exert significant anti-tumor growth and metastasis effects in vivo and in vitro. These significant results show that inhibiting the overexpression of CTTN is a potential effective method for treating cancer or tumors. There have been no previous reports indicating that CTTN can regulate cell senescence. Therefore, the present invention promotes tumor cell senescence, inhibits tumor growth and metastasis by targeting CTTN of tumor cells, and has potential medical transformation value. This technology can be used as a novel technology to induce cell senescence in tumor cells.
[0026] Unless otherwise specified, all tests in the present invention were performed under standard conditions, including room and test temperature of 25°C, sea level (1 atm.) pressure, pH of 7, and all measurements were performed in metric units. Data quantification is expressed as mean±sem, and asterisks indicate *, P<0.05; **, P<0.01; *** P<0.001. NCG experimental mice were purchased from Jicui Pharmaceuticals, and antibodies were mainly purchased from Cell Signaling Technology (CST) and Abclonal.
[0027] Experimental Materials Manufacturer / Article No. 6-week-old NCG mice Jicui Pharmaceuticals CTTN Antibody CST, #3503S Lamin B1 Antibody Abclonal, #A16909 p53 Antibody CST, #2527 p21 antibody CST, #2947S p-RB (Ser807 / 811) Antibody CST, #8516S
[0028] Example 1 Relevant components and principles of constructing a lentiviral system for interfering with CTTN mRNA expression
[0029] 1. The relevant components are shown in Table 1:
[0030] Table 1 Relevant components for constructing the lentiviral system for interfering with CTTN mRNA expression
[0031]
[0032]
[0033] 2. The principle of RNA interference by shRNA
[0034] RNA interference (RNAi) refers to the fact that some small double-stranded RNA (dsRNA) can efficiently and specifically block the expression of specific genes in the body and promote the degradation of mRNA.
[0035] ① After the plasmid or virus particle encoding shRNA enters the host cell genome, it transcribes shRNA (short hairpin RNA, locally forming a double-stranded RNA structure). The nuclease Dicer in the cytoplasm cuts these shRNAs with double-stranded RNA structures into short double-stranded RNAs with specific length and structure (about 21 to 25 bp), namely siRNA.
[0036] ② Under the action of RNA helicase, siRNA is unzipped into a sense strand and an antisense strand, and then the antisense siRNA combines with some enzymes in the body to form an RNA-induced silencing complex (RISC).
[0037] ③RISC specifically binds to the homologous region of the target mRNA through antisense siRNA. RISC has the function of nuclease, which cuts mRNA at the binding site, and the broken mRNA is degraded immediately after cutting.
[0038] ④ Amplification of RNAi signals: siRNA can not only guide RISC to cut homologous single-stranded mRNA, but also act as a primer to bind to the target RNA and synthesize more new dsRNA under the action of RNA-dependent RNA polymerase (RNdependent RNA polymerase, RdRP). The newly synthesized dsRNA is then cut by Dicer to produce a large number of secondary siRNAs, thereby further amplifying the effect of RNAi and ultimately completely degrading the target mRNA.
[0039] The embodiment of the present invention relates to a short hairpin RNA (shRNA) for inhibiting the expression of CTTN, which comprises an RNAi molecule with a length of 21 nt. The RNAi molecule is divided into a sense strand and an antisense strand, wherein the sense strand sequence is consistent with the target sequence on the CTTN mRNA, and the antisense strand of the RNAi molecule is complementary to the target sequence on the CTTN gene mRNA.
[0040] Example 2 Sequence of CTTN shRNA in the present invention
[0041] The shRNA for inhibiting CTTN expression provided by the present invention is composed of the nucleotide sequence 5′-CCGG-sense strand of the RNAi molecule-CTCGAG-antisense strand of the RNAi molecule-TTTTTG-3′. The sense strand sequence of the RNAi molecule contained in the shRNA targeting CTTN mRNA designed by the present invention is as follows:
[0042] The sense strand sequence of the RNAi molecule contained in CTTN shRNA1 is:
[0043] SEQ ID NO. 1: 5'-GTAACATCAGAGCTAACTTTG-3'.
[0044] The sense strand sequence of the RNAi molecule contained in CTTN shRNA2 is:
[0045] SEQ ID NO. 2: 5'-CCACAGAATTTGCTAATATAT-3'.
[0046] The sense strand sequence of the RNAi molecule contained in CTL shRNA (negative control of shRNA) is: 5'-GTTCCGTCATAGCGATAACGA-3'
[0047] Example 3 Working principle of lentiviral particle delivery system and construction of shRNA shuttle plasmid
[0048] 1. Working principle of lentiviral particle delivery system
[0049] The present invention uses lentiviral particles to infect cells to deliver the shRNA expression system into target cells. The main sequences of the lentiviral genome include LTR, GAG, POL, TAT, REV, ENV (VSV-G), etc. ( Figure 1 ). Scientists split the main genome sequence of the lentivirus into three parts and constructed three plasmids, packaging plasmid, envelope plasmid and transfer plasmid. These three plasmids were co-transfected into 293T cells to package into infectious lentiviral particles. The shuttle plasmid used in this invention is pLKO-tet-on plasmid. When these lentiviral particles infect the target cells, the sequences between the LTRs in the shuttle plasmid (such as Figure 2The sequence shown in Figure 1 can be integrated into the genome of the target cell, that is, the lentiviral particles successfully deliver shRNA and related regulatory elements to the target cell. The sequence integrated into the target cell can be transcribed into shRNA. shRNA will be processed into siRNA in the cell, exerting RNA interference, degrading the target mRNA, and ultimately reducing the expression of the target protein.
[0050] In this embodiment, psPAX2, VSVG and pLKO-tet-on plasmids are co-transfected into 293T cells, which are packaged into lentiviral particles carrying shRNA sequence information by 293T cells. Lentivirus particles are used to infect target cells, such as Mel167, A375 melanoma cells and BRx50 breast cancer cells. The shuttle plasmid used in the present invention is a pLKO-tet-on plasmid carrying shRNA related elements. The key elements of the pLKO-tet-on plasmid map are as follows Figure 2 As shown. H1promoter and Tet operator are cis-regulatory elements that regulate shRNA transcription; TerR protein expressed by TerR gene can bind to Tet operator, thereby inhibiting shRNA transcription. When Doxycycline is added, it can bind to TerR protein and make the latter separate from Tet operator, so Tet operator can play a normal function and transcribe shRNA; PuroR gene encodes protein that can give cells the ability to resist puromycin, that is, cells infected by the lentivirus can resist the toxic effects of puromycin, while uninfected cells will be killed by puromycin, so puromycin can be used to screen out cells positively infected by lentivirus.
[0051] 2. Construction of shRNA shuttle plasmid
[0052] According to the designed shRNA sequence, design the required forward primer and reverse primer, such as: Forward primer:
[0053] 5′-CCGG-sense strand of the RNAi molecule-CTCGAG-antisense strand of the RNAi molecule-TTTTTG-3′;
[0054] Reverse Primer:
[0055] 5'-AATTCAAAAA-sense strand of the RNAi molecule-CTCGAG-antisense strand of the RNAi molecule-3';
[0056] The forward and reverse primers of shRNA were synthesized by Sangon Biotech (Shanghai) Co., Ltd. After obtaining the primers, the forward and reverse primers of shRNA were annealed to form double strands. The pLKO-tet-on vector was digested with restriction enzymes AgeI (NEB, R3552S) and EcoRI (NEB, R3101s). Then, the annealed shRNA fragment was ligated to the digested pLKO-tet-on vector using T4 ligase to form the pLKO-tet-on-CTTN shRNA plasmid.
[0057] Example 4 Preparation of Lentiviral Particles and Infection of Target Cells with Lentiviral Particles
[0058] 1. Preparation of Lentiviral Particles
[0059] The psPAX2 packaging plasmid, VSVG envelope plasmid and pLKO-tet-on CTL shRNA or pLKO-tet-on-CTTN shRNA plasmid were co-transfected into 293T cells, and the latter was able to package and secrete lentiviral particles into the cell culture medium. The specific operation is as follows:
[0060] First, inoculate 293T into a 10 cm cell culture dish. On the next day, add 7.1 μg psPAX2, 2.35 μg VSVG and 6.4 μg pLKO-tet-on or pLKO-tet-on-CTTN shRNA plasmid to 0.6 ml serum-free DMEM culture medium to form a DNA mixture. In addition, add 47.55 μg PEI (Polyethylenamine) to 0.6 ml serum-free DMEM culture medium to form a PEI dilution solution. Then mix the DNA mixture with the PEI dilution solution, place it at room temperature, and incubate for 15 minutes. Remove the DMEM culture medium (containing 10% FBS) in the 293T culture dish and add 10 ml of new DMEM culture medium (containing 10% FBS). Then add the incubated DNA-PEI mixture dropwise into the 293T culture dish. The cells were transferred to a cell culture incubator (37°C, 5% CO2). After 60 hours, the culture medium containing virus particles was collected and filtered using a filter with a pore size of 0.45 μm. The virus solution was collected and divided into 1.5 ml centrifuge tubes and stored in a -80°C refrigerator.
[0061] 2. Infection of target cells with lentiviral particles
[0062] The cells used in the present invention include human melanoma cell lines Mel167, A375 and breast cancer cells BRx50. Mel167 and BRx50 were cultured in CTC culture medium (RPMI-1640, 20ng / ml EGF, 20ng / ml bFGF), and A375 was cultured in DMEM, 10% fetal bovine serum (FBS) culture medium. In order to establish Mel167-plko-tet-on and A375-plko-tet-on CTTN shRNA cell lines, the cells were first inoculated in a 6-well plate or T25 culture flask, and then 0.5ml of pLKO-tet-on CTL shRNA and pLKO-tet-on CTTN shRNA1 / 2 lentiviral particles were added, and polybrene with a final concentration of 2 to 8μg / ml was added to enhance the infection efficiency. After 18 hours of adding lentiviral particles, the culture medium was replaced with a new one. After 2 days, puromycin with a final concentration of 0.5-1 μg / ml was added for screening. After 3 days of puromycin screening, positive stable cell lines infected with lentivirus were obtained.
[0063] Example 5 Detection of the silencing efficiency of CTTN shRNA on CTTN expression
[0064] After obtaining a stable cell line, 300ng / ml of doxycycline was added to treat the cells for 3 days, and then the total RNA and total protein of the cells were collected for RT-qPCR to detect the expression value of CTTN mRNA and immunoblotting to detect the protein expression of CTTN. Doxycycline is used to activate the promoter of shRNA and induce the transcription of shRNA. Subsequently, shRNA can induce the degradation of CTTN mRNA and reduce the content of CTTN protein. The experimental results show that the designed shRNA can effectively inhibit the expression of CTTN mRNA in tumor cells ( Figure 3 A) and protein expression ( Figure 3 BD).
[0065] Example 6: shRNA silencing of CTTN expression can induce cellular senescence in melanoma cells
[0066] When cells undergo senescence, the expression of p53 (TP53) and p21 (CDKN1A) increases, the expression of p-RB (phosphorylated RB1), Ki-67 (MKI67) and Lamin B1 (LMNB1) decreases, and the content of beta-galactosidase increases. These proteins have now become markers for identifying senescent cells.
[0067] Mel167-teton-CTTN shRNA, Mel167-teton-CTL (shRNA negative control), A375-teton-CTTN shRNA, A375-teton-CTL (shRNA negative control) were inoculated into T25 cell culture flasks or 6-cm cell culture dishes, and cell culture medium containing doxycycline at a final concentration of 300ng / ml was added and cultured for 3 days. After 3 days, the cells were collected by centrifugation, RIPA cell lysis buffer was added, and protein was extracted. Conventional immunoblotting was used to detect cell CTTN expression and the expression of cell senescence markers such as p53 (TP53), p21 (CDKN1A), phosphorylated RB (p-RB) and Lamin B1 (LMNB1). The results showed that knocking down CTTN in Mel167 and A375 could significantly increase the expression of p53 and p21, and reduce the protein expression of p-RB and Lamin B1 ( Figure 4 A and B).
[0068] In addition, after doxycycline induced CTTN shRNA expression, total RNA of cells was extracted, and RT-qPCR was used to detect the mRNA expression values of Ki-67 (MKI67) in Mel167 and A375 with knockdown of CTTN expression. The results showed that after knockdown of CTTN expression, the Ki-67 mRNA of cells decreased significantly ( Figure 4 C and D).
[0069] This example also used a cell senescence β-galactosidase staining kit (Biosharp, catalog number BL133A) to stain A375 cells with CTTN knocked down (the staining process was performed according to the instructions of the kit). The results showed that after knocking down CTTN expression, the β-galactosidase content of the cells increased significantly ( Figure 4 E and F).
[0070] Knockdown of CTTN did not increase the expression of p-ATM, p-ATR, and p-H2A.x, indicating that it did not cause cellular DNA damage ( Figure 4 G). In addition, silencing the expression of p53 can reduce the expression of p21 to a certain extent and increase the expression of p-RB, Lamin B1, and Ki-67 ( Figure 4 H and I), indicating that tumor cell senescence induced by knockdown of CTTN expression is dependent on the activation of p53.
[0071] In summary, the CTTN shRNA designed in the present invention can effectively silence the CTTN expression of tumor cells, activate p53, and induce cell senescence of tumor cells.
[0072] Example 7 shRNA silencing of CTTN expression can significantly inhibit the growth and metastasis of tumor cells in vitro and in vivo
[0073] 1. Determination of tumor cell proliferation in vitro
[0074] This example uses the CellTiter-Glo luminescent cell viability assay (Promega # G7571) to determine cell proliferation. Mel167-teton-CTTN shRNA, Mel167-teton-CTL (shRNA negative control), A375-teton-CTTN shRNA, A375-teton-CTL (shRNA negative control) were inoculated in a 96-well plate (Corning No. 3610), and doxycycline was added at a final concentration of 300ng / ml. After 3 days, 50μL CellTiter Glo reagent (Promega # G7571) was added to each well and incubated at room temperature for 10 minutes. Then a multifunctional microplate reader (BioTek Synergy TM H1 multifunctional microplate reader) to read the chemiluminescent signal. The results showed that ( Figure 5 A and B) Silencing the expression of CTTN can effectively inhibit the in vitro growth of melanoma cells. At the same time, knocking down the expression of CTTN can also effectively inhibit the in vitro growth of breast cancer cells BRx50 ( Figure 5 C).
[0075] 2. Determining tumor growth in mouse models
[0076] NCG mice were randomly divided into groups, with 6-8 mice in each group. 100 μl of Mel167-teton CTTNshRNA cells containing 700,000 were mixed with 50% Matrigel (Corning, #356237) and injected subcutaneously into the back of NCG mice. Sucrose with a final concentration of 20 g / L and an aqueous solution of 1 mg / ml doxycycline were added to the drinking water of the mice to induce the expression of CTTN shRNA in tumor cells. Every few days, the long and short diameters of the tumor were measured using a vernier caliper. The tumor volume was counted and the growth curve of the tumor was drawn. The results showed that ( Figure 5 DF), using shRNA to deliver RNAi molecules targeting CTTN mRNA to knock down the expression of CTTN can significantly inhibit tumor growth.
[0077] 3. Determination of tumor metastasis in mouse models
[0078] Mel167 cells that stably expressed luciferase were infected with the lentiviral particles prepared in Example 4 to establish a cell line. NCG mice were randomly divided into groups of 8 mice each. 700,000 Mel167-teton CTTNshRNA cells were resuspended in phosphate buffered saline (PBS) and the tumor cells were injected into the mice via tail vein injection.
[0079] 15mg / ml luciferase substrate (luciferin, PerkinElmer #122799) was prepared with PBS and injected intraperitoneally at a volume of 10μl / g according to the weight of the mouse. 10 minutes after the substrate injection, the mice were anesthetized with isoflurane and placed in a small animal in vivo imager (PerkinElmer #IVIS Spectrum In Vivo Imaging System) to perform fluorescence imaging of tumor cells in NCG mice. The fluorescence readings were counted and the growth curve of metastatic tumors was drawn. The results showed that after shRNA silenced the expression of CTTN, the metastasis of the tumor was significantly reduced ( Figure 5 G and H).
[0080] Example 8 High expression of CTTN mRNA is associated with shorter survival in patients with various tumors
[0081] The GEPIA online analysis platform (http: / / gepia.cancer-pku.cn / index.html) and TCGA datasets were used to analyze the overall survival of patients with skin melanoma (SKCM), hepatocellular carcinoma (LIHC), head and neck squamous cell carcinoma (NHSC), lung squamous cell carcinoma (LUSC), brain low-grade glioma (LLG), and pancreatic cancer (PAAD). The overall survival analysis of breast cancer patients was analyzed using the BCIP online platform (http: / / omicsnet.org / bcancer / database) to analyze the Metabric dataset. The results showed that high expression of tumor CTTN mRNA in these cancer patients was associated with shorter survival ( Figure 6 ). This suggests that CTTN may play an important role in promoting cancer in the occurrence and development of various tumors, including melanoma and breast cancer.
[0082] In summary of the above embodiments, the present invention uses lentiviral particles to deliver the shRNA targeting CTTN mRNA designed in the present invention (including the RNAi small molecules contained therein) into human tumor cells. The designed shRNA can effectively inhibit the expression of CTTN protein in Mel167 and A375 cells ( Figure 3); The CTTN shRNA designed in the present invention can effectively silence the expression of CTTN in tumor cells, activate the tumor suppressor gene p53, and induce cell senescence in tumor cells ( Figure 4 ), silencing the expression of CTTN can effectively inhibit the growth of tumor cells in vitro. After shRNA silencing the expression of CTTN, the metastasis of the tumor was significantly reduced ( Figure 5 ). Using shRNA to deliver RNAi molecules targeting CTTN mRNA and knocking down the expression of CTTN can significantly inhibit tumor growth ( Figure 6 ). Therefore, inducing tumor cell senescence by targeting CTTN has potential application value in anti-tumor growth and metastasis.
[0083] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
[0084]
Claims
1. A shRNA for inhibiting CTTN expression, characterized in that: The shRNA comprises a sense strand of an RNAi molecule and an antisense strand of an RNAi molecule, wherein the antisense strand of the RNAi molecule hybridizes with a target sequence on the CTTN gene mRNA, and the nucleotide sequence of the shRNA is CCGG-sense strand of the RNAi molecule-CTCGAG-antisense strand of the RNAi molecule-TTTTTG.
2. The shRNA according to claim 1, characterized in that The nucleotide sequence of the sense strand in the RNAi molecule contained in the shRNA is any one of SEQ ID NO.1 and SEQ ID NO.
2.
3. A gene delivery system comprising the shRNA sequence described in claim 1 or 2.
4. The gene delivery system according to claim 3, characterized in that The gene delivery system includes but is not limited to viral vectors, liposomes, and nanoparticles.
5. The gene delivery system according to claim 3, characterized in that The viral vector is a lentiviral vector pLKO-tet-on.
6. Use of the shRNA according to any one of claims 1 to 2 or the gene delivery system according to any one of claims 3 to 5 in the preparation of a drug for treating tumors.
7. Use of the shRNA according to any one of claims 1 to 2 or the gene delivery system according to any one of claims 3 to 5 in the preparation of a drug for inducing tumor cell senescence.
8. Use of the shRNA according to any one of claims 1 to 2 or the gene delivery system according to any one of claims 3 to 5 in the preparation of a drug for activating p53.
9. The method for preparing the gene delivery system according to any one of claims 3 to 5, characterized in that: The method comprises the following steps: transferring the shRNA into a gene delivery system.
10. The preparation method according to claim 9, characterized in that: The gene delivery system includes but is not limited to viral vectors, liposomes, and nanoparticles.
